Johnson & Johnson insider trading
Every open-market purchase and sale by Johnson & Johnson's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Johnson & Johnson’s insiders pay?
From February 12, 2010 to September 4, 2026, 35 insiders reported 18 open-market purchases and 124 sales not made under a pre-set plan in Johnson & Johnson. Twelve months after each purchase was reported, the shares were −3.9% against the S&P 500 on average (median −5.8%), over 17 purchases with a full year of prices; 35% beat the index. After sales, the shares moved −4.9% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on February 16, 2010 into $56,139 by November 2, 2026, +10.9% a year. It held shares 53% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $41,784 (+8.9% a year), and held throughout $92,597 (+14.3%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Fasolo Peter | Exec VP, Chief HR Officer | 0 | — | — | 15 | −18.0% (15) | July 27, 2023 |
| Perez William D | Director | 9 | −11.2% (9) | 22% | 0 | — | March 17, 2020 |
| Kapusta Ronald A | Controller, CAO | 0 | — | — | 8 | −7.1% (8) | December 14, 2018 |
| Caruso Dominic J | Exec VP, Finance; CFO | 0 | — | — | 7 | −1.8% (7) | July 24, 2017 |
| Cullen James | Director | 0 | — | — | 7 | −0.7% (7) | September 11, 2014 |
| Decker Robert J | VP Corporate Controller | 0 | — | — | 7 | +1.5% (6) | March 3, 2026 |
| Cosgrove Stephen J | Corporate Controller | 0 | — | — | 6 | −1.7% (6) | November 7, 2014 |
| Deyo Russell C | VP, General Counsel | 0 | — | — | 6 | +3.8% (6) | February 23, 2012 |
| Duato Joaquin | CEO and Chairman of the Board | 0 | — | — | 6 | +0.4% (3) | August 14, 2026 |
| Stoffels Paulus | Exec VP, Chief Scientific Off | 0 | — | — | 6 | −2.2% (6) | February 20, 2018 |
| Wengel Kathryn E | EVP, Chief TO and Risk Officer | 0 | — | — | 6 | −21.1% (5) | June 12, 2026 |
| Weldon William C | Chairman/CEO | 0 | — | — | 5 | +4.3% (5) | September 11, 2012 |
| Mongon Thibaut | Exec VP, WW Chair, Consumer | 0 | — | — | 4 | −10.2% (4) | November 8, 2022 |
| Prince Charles | Director | 4 | +7.2% (4) | 75% | 0 | — | December 17, 2018 |
| Schmid Timothy | EVP, WW Chair, MedTech | 0 | — | — | 4 | +43.2% (1) | September 4, 2026 |
| Sneed Michael E | EVP, Global Corp Aff & COO | 0 | — | — | 4 | −12.6% (4) | December 10, 2020 |
| Taubert Jennifer L | EVP, WWC. Innovative Medicine | 0 | — | — | 4 | −4.7% (3) | August 18, 2026 |
| Ullmann Michael H | Exec VP, General Counsel | 0 | — | — | 4 | −2.0% (4) | February 3, 2017 |
| Wolk Joseph J | Exec VP, CFO | 0 | — | — | 4 | +15.6% (3) | February 18, 2026 |
| Broadhurst Vanessa | EVP, Global Corp Affairs | 0 | — | — | 3 | −3.9% (1) | July 21, 2026 |
| Hait William | See Remarks | 0 | — | — | 3 | −19.5% (3) | July 27, 2023 |
| Reed John C | EVP, Innovative Medicine, R&D | 0 | — | — | 3 | +33.4% (2) | February 18, 2026 |
| Mccoy Sherilyn S | Member, Executive Committee | 0 | — | — | 2 | −0.7% (2) | November 17, 2011 |
| Mcevoy Ashley | EVP, WW Chair, MedTech | 0 | — | — | 2 | −21.1% (2) | December 2, 2022 |
| Pruden Gary J | Exec VP, WW Chair, Med Devices | 0 | — | — | 2 | −5.7% (2) | March 2, 2017 |
| Swanson James D. | EVP, CIO | 0 | — | — | 2 | −22.7% (1) | February 18, 2026 |
| Forminard Elizabeth | EVP, Chief Legal Officer | 0 | — | — | 1 | — | August 7, 2026 |
| Goggins Colleen A | Member, Executive Committee | 0 | — | — | 1 | +2.1% (1) | September 13, 2010 |
| Gorsky Alex | Chairman, CEO | 0 | — | — | 1 | −23.2% (1) | November 16, 2018 |
| Hewson Marillyn A | Director | 1 | −4.2% (1) | 0% | 0 | — | June 11, 2019 |
| Joly Hubert | Director | 1 | −11.0% (1) | 0% | 0 | — | December 16, 2019 |
| Lindquist Susan L | Director | 0 | — | — | 1 | +7.6% (1) | December 10, 2012 |
| Morikis John G | Director | 1 | — | — | 0 | — | December 1, 2025 |
| Mulcahy Anne M | Director | 1 | −14.9% (1) | 0% | 0 | — | December 17, 2018 |
| Weinberger Mark A | Director | 1 | +35.4% (1) | 100% | 0 | — | December 12, 2024 |
When several insiders traded Johnson & Johnson
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Johnson & Johnson in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 1 buying crowd with six months of prices, it averaged −9.1% against the index. After 16 selling crowds, −3.3%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| August 31, 2026 | 5 selling | not yet | not yet | not yet |
| February 27, 2026 | 6 selling | −19.4% | −3.7% | not yet |
| August 29, 2025 | 3 selling | +11.3% | +34.8% | +37.1% |
| February 28, 2025 | 3 selling | −4.6% | −0.1% | +37.8% |
| July 31, 2023 | 3 selling | −2.5% | −11.8% | −24.8% |
| November 30, 2022 | 6 selling | −12.4% | −16.4% | −22.7% |
| April 29, 2022 | 3 selling | −3.1% | +3.0% | −7.5% |
| February 28, 2020 | 3 selling | +8.1% | −3.5% | −12.3% |
| February 28, 2019 | 3 buying | −3.2% | −9.1% | −7.2% |
| November 30, 2018 | 4 selling | −5.9% | −11.0% | −18.5% |
| March 31, 2017 | 5 selling | +3.8% | −1.9% | −7.0% |
| July 29, 2016 | 3 selling | −5.7% | −14.4% | −7.1% |